<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
    </SeriesInfo>
    <SeriesHeader>
      <EditorGroup>
        <Editor AffiliationIDS="Aff1">
          <EditorName DisplayOrder="Western">
            <GivenName>J.M.</GivenName>
            <FamilyName>Walker</FamilyName>
          </EditorName>
        </Editor>
        <Affiliation ID="Aff1">
          <OrgName>School of Life Sciences University of Hertfordshire</OrgName>
          <OrgAddress>
            <City>Hatfield</City>
            <State>Hertfordshire, AL10 9AB</State>
            <Country>UK</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </SeriesHeader>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
        <BookID>978-1-60327-527-9</BookID>
        <BookTitle>T Cell Protocols</BookTitle>
        <BookSubTitle>Second Edition</BookSubTitle>
        <BookVolumeNumber>514</BookVolumeNumber>
        <BookSequenceNumber>514</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-527-9</BookDOI>
        <BookTitleID>145011</BookTitleID>
        <BookPrintISBN>978-1-58829-587-3</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-527-9</BookElectronicISBN>
        <BookChapterCount>11</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="SCL" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="SCL14005" Priority="1" Type="Secondary">Biochemistry, general</BookSubject>
          <BookSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</BookSubject>
          <BookSubject Code="SCL16020" Priority="3" Type="Secondary">Cell Culture</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor AffiliationIDS="Aff2">
            <EditorName DisplayOrder="Western">
              <GivenName>Gennaro</GivenName>
              <Particle>De</Particle>
              <FamilyName>Libero</FamilyName>
            </EditorName>
            <Role>Dr</Role>
            <Contact>
              <Email>Gennaro.DeLibero@unibas.ch</Email>
            </Contact>
          </Editor>
          <Affiliation ID="Aff2">
            <OrgName>University of Basel</OrgName>
            <OrgAddress>
              <State>Basel</State>
              <Country>Switzerland</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Chapter ID="Chap2" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
          <ChapterID>2</ChapterID>
          <ChapterNumber>Chapter 2</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-527-9_2</ChapterDOI>
          <ChapterSequenceNumber>2</ChapterSequenceNumber>
          <ChapterTitle Language="En">B Cell Helper Assays</ChapterTitle>
          <ChapterFirstPage>15</ChapterFirstPage>
          <ChapterLastPage>26</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2009</CopyrightYear>
          </ChapterCopyright>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-527-9</BookID>
            <BookTitle>T Cell Protocols</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Sergio</GivenName>
                <FamilyName>Abrignani</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff4">
              <AuthorName DisplayOrder="Western">
                <GivenName>Elena</GivenName>
                <FamilyName>Tonti</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff4">
              <AuthorName DisplayOrder="Western">
                <GivenName>Giulia</GivenName>
                <FamilyName>Casorati</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff4">
              <AuthorName DisplayOrder="Western">
                <GivenName>Paolo</GivenName>
                <FamilyName>Dellabona</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff3">
              <OrgName>Istituto Nazionale di Genetica Molecolare-INGM</OrgName>
              <OrgAddress>
                <City>Milan</City>
                <Country>Italy</Country>
              </OrgAddress>
            </Affiliation>
            <Affiliation ID="Aff4">
              <OrgDivision>Experimental Immunology Unit, Cancer Immunotherapy and Gene Therapy Program, Department of Biology and Biotechnology</OrgDivision>
              <OrgName>San Raffaele Scientific Institute</OrgName>
              <OrgAddress>
                <City>Milan</City>
                <Country>Italy</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1" Language="En">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Activation, proliferation and differentiation of naïve B lymphocytes into memory B cells and plasma cells requires engagement of the B cell receptor (BCR) coupled to T-cell help <CitationRef CitationID="CR1">(1</CitationRef>, <CitationRef CitationID="CR2">2)</CitationRef>. T cells deliver help in cognate fashion when they are activated upon recognition of specific MHC–peptide complexes presented by B cells. T cells can also deliver help in a non-cognate or bystander fashion, when they do not find specific MHC–peptide complexes on B cells and are activated by alternative mechanisms. T-cell dependent activation of B cells can be studied in vitro by experimental models called “B cell helper assays” that are based on the co-culture of B cells with activated T cells. These assays allow to decipher the molecular bases for productive T-dependent B cell responses. We show here examples of B cell helper assays in vitro, which can be reproduced with any subset of T lymphocytes that displays the appropriate helper signals.</Para>
          </Abstract>
          <KeywordGroup Language="En">
            <Heading>Key Words</Heading>
            <Keyword>Helper assay</Keyword>
            <Keyword>NKT cells</Keyword>
            <Keyword>B cells</Keyword>
            <Keyword>Ig response</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" OutputMedium="Online" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">The help of CD4<Superscript>+</Superscript> T cells to B cells in secondary lymphoid organs leads to B cell expansion, the generation of short-lived antibody-secreting cells (ASCs) and, following the germinal centre reaction, to high-affinity memory B cells and long-lived plasma cells. This interaction requires presentation of processed antigens by B cells to specific CD4<Superscript>+</Superscript> T cells, signalling by costimulatory molecules such as CD40 on B cells, and production of cytokines by activated T cells. The T–B interaction can be reproduced in vitro, using an experimental system called B cell helper assay. Lanzavecchia <CitationRef CitationID="CR1">(1</CitationRef>, <CitationRef CitationID="CR2">2)</CitationRef> showed that human CD4<Superscript>+</Superscript> T cell clones can activate B cells to proliferate and to differentiate into plasmacytoid ASCs that secrete Ig of all classes in vitro. B cell helper assays in vitro proved to be extremely useful to dissect the molecular mechanisms involved in the reaction. Two types of T-dependent help were recognised owing to different experimental designs: (i) cognate, whereby the TCR expressed by CD4<Superscript>+</Superscript> T cells interacts with cognate peptide–MHC class II complexes presented by B cells; and (ii) non-cognate, whereupon T cells, activated by third party antigen (e.g. the TCR is engaged by peptide/MHC-II expressed by other APCs, by polyclonal stimuli such as anti-CD3 mAbs, etc.), interact with B cells that do not display their cognate peptide/MHC-II complexes, yet deliver costimulatory signals sufficient to trigger B cell activation in a bystander manner. In both experimental conditions T cells are armed to induce B cell proliferation and differentiation via CD40 ligand and cytokine production. We have exploited B cell helper assays to investigate in vitro the helper function of a non-conventional subset of T lymphocyte, called invariant (i)NKT cells. Unlike conventional peptide-specific and MHC-restricted T cells, iNKT cells recognise lipid antigens presented by CD1d molecules, which are non-MHC encoded class I-like molecules <CitationRef CitationID="CR3">(3)</CitationRef>. iNKT cells express a characteristic conserved semi-invariant TCR α chain, composed by the homologue invariant Vα14-Jα18 and Vα24-Jα18 rearrangements paired with Vβ8.2, Vβ7 or Vβ2 and Vβ11 in mice and men, respectively <CitationRef CitationID="CR4">(4)</CitationRef>. Both human and mouse iNKT cells can be unequivocally identified and purified exploiting their TCR: human cells are identified using either a combination of anti-Vα24 and anti-Vβ11-specific mAb or fluorescent multimers of human recombinant soluble CD1d in complex with the glycosphingolipid αGalactosylCeramide (αGalCer) <CitationRef CitationID="CR5">(5</CitationRef>, <CitationRef CitationID="CR6">6)</CitationRef>. Mouse iNKT cells are identified using fluorescent multimers of mouse recombinant CD1d molecules loaded with αGalCer <CitationRef CitationID="CR7">(7</CitationRef>, <CitationRef CitationID="CR8">8)</CitationRef>. Upon activation, iNKT cells produce swiftly many different cytokines and upregulate CD40L; in turn, they induce the activation of cellular effectors of the innate (MΦ, DC, NK) as well as acquired (T, B) immune system <CitationRef CitationID="CR4">(4</CitationRef>, <CitationRef CitationID="CR9">9)</CitationRef>. iNKT can be divided into two major subsets, depending on the expression of CD4 coreceptor <CitationRef CitationID="CR10">(10</CitationRef>, <CitationRef CitationID="CR11">11)</CitationRef>. The iNKT CD4<Superscript>+</Superscript> subset exhibits, particularly in humans, prominent helper effector functions, characterised by the expression of a The cytokine pattern, whereas the iNKT CD4<Superscript>-</Superscript> one exhibit a more polarised Th1-like effector functions and are less efficient in providing B cell help. We have utilised B cell helper assays in vitro to demonstrate that both human and mouse iNKT cells activate human or mouse B cells, respectively, to proliferate and differentiate into IgM and IgG ASCs <CitationRef CitationID="CR12">(12</CitationRef>, <CitationRef CitationID="CR13">13)</CitationRef> (and E. Tonti unpublished data). We outline here the experimental procedures of the B cell helper assay, consisting essentially in the: (i) Generation of clones or polyclonal lines of human and mouse iNKT cells, respectively; (ii) Purification of primary resting human and mouse B cells; and (iii) iNKT and B cells co-culture system to investigate both cognate and bystander help provided by iNKT cells to B cells. T cell-induced B cell proliferation can be quantified by determining the incorporation of <Superscript>3</Superscript>H-thymidine into the DNA synthesised by dividing cells. Alternatively, B cells proliferation in response to iNKT helper activity in vitro can be investigated by labelling B cells with carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) and determining the progressive dilution of the fluorescent dye upon cell-division. Furthermore, B cells activated by T cells in vitro differentiate into plasmablasts that upregulate CD27 and downregulate CD20, allowing their identification and quantification by flow cytometry. This method is particularly informative when coupled with the use of CFDA-SE dilution to determine B cell division in vitro T cell helper activity in vitro leads not only to B cell division but also to differentiation to ASCs. The degree of differentiation of B cells to ACSs in vitro can be quantified by determining the concentration of secreted Igs in the culture supernatant. Finally, B cell helper assays in vitro can be performed with mouse cells as well. Mouse B cells are purified from the spleen using anti-CD19 mAb coupled magnetic MicroBeads. Mouse iNKT cells can be purified from spleen following two different methods. In the first, iNKT cells can be sorted exploiting their expression of the NK receptor NK1.1 (CD161). In this case, one has to be aware that iNKT cells represents only up to 30% of total NK1.1<Superscript>+</Superscript> T cells in the spleen. We have found that a previous depletion of NK cells in vivo, by injecting into mice the NK-specific anti-AsialoGM1 antiserum, facilitates greatly the subsequent purification in vitro of NKT cells. In the second method, iNKT cells are identified from the other NK1.1<Superscript>+</Superscript> T cells by the binding of αGalCer-loaded CD1d–IgG1 dimers to their TCR. Dimers bound to iNKT cells are revealed using a PE-labelled rat-anti-mouse IgG1 mAb and stained cells are sorted by fluorescent-based automated cell sorting or by magnetic microbeads coupled to anti-PE mAb.</Para>
          </Section1>
          <Section1 ID="Sec2" OutputMedium="Online">
            <Heading>Materials</Heading>
            <Section2 ID="Sec3" OutputMedium="Online">
              <Heading>Buffers, Media and Supplements for Cell Culture</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RPMI complete medium: RPMI–Glutamax medium (Gibco) containing 10% FCS (HyClone), non-essential amino acids, 1 mM sodium pyruvate and kanamycin or penicillin plus streptomycin (Gibco), 2.5×10<Superscript>–5</Superscript> M 2-<Emphasis Type="Italic">β</Emphasis>mercapto ethanol (2-ME).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">FACS-wash: PBS containing 1% FCS and 0.05% NaN<Subscript>3</Subscript>, filtered with 0.2 μm filters and kept at +4°C</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">FACS-sorting: PBS containing 1% FCS filtered with 0.2 μm filters and kept at +4°C</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Recombinant human cytokines: IL-2 (Novartis), IL-4 and IL-13 (R&amp;D Systems). Once lyophilised cytokines are dissolved in complete medium they can be aliquoted and stored at –80°C over 1 year. Working aliquots can be kept at +4°C for not more than 2–3 months.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Recombinant mouse cytokine: IL-7 (R&amp;D Systems) dissolved and stored as described above.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Superscript>3</Superscript>H-Thymidine (<Superscript>3</Superscript>H-TdR) (1 µCi/well, 6.7 Ci/mol; Amersham Corp.), keep at +4°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">αGalactosylCeramide (Alexis) is dissolved at a concentration of 200 μg/ml in 0.9% (w/v) NaCl + 0.5% (v/v) polysorbate (Tween 20, Sigma Aldrich) and kept at 37°C for 16 h. To completely dissolve αGalCer, DMSO is added to the solution at a final concentration of 2% (v/v). The solution is kept at 60°C for 15 min then aliquoted in glass tubes and stored at 4°C. This αGalCer solution can be kept at 4°C for several months since its activity is very stable. Before use, each aliquot is heated at 65°C for 10 min, vortex for 3 min, and then kept at 37°C for not less than 60 min.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">CarboxyFluorescein Diacetate Succinimidyl Ester (CFDA-SE, Molecular Probes, Leiden, The Netherlands) dissolved in DMSO at 50 mM. Stock aliquots of this solution can be prepared in polypropylene microtubes and stored at –20°C in the dark. When properly protected from the light, CFDA-SE aliquots can be thawed and frozen several times.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">C1R LCL cells engineered with hCD1d <CitationRef CitationID="CR14">(14)</CitationRef>. Cells are grown in complete RPMI medium supplemented with 0.5 mg/ml G418. Wilde type (wt) C1R LCL cells are grown in complete RPMI medium.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">ACK solution: 150 mM NH<Subscript>4</Subscript>Cl, 10 mM KHCO<Subscript>4</Subscript>, 0.1 mM Na<Subscript>2</Subscript>EDTA pH 7.2–7.4 filter sterile, keep at +4°C.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec4" OutputMedium="Online">
              <Heading>Antibodies</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Specific monoclonal antibodies used with human cells:<OrderedList>
                          <ListItem>
                            <ItemNumber>a.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Non-immune mouse IgG (Becton Dickinson)</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>b.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-V<Emphasis Type="Italic">β</Emphasis>11 (C21, mouse IgG2a), anti-Vα24 (C15, mouse IgG1) (Immunotech, Marseille, France).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>c.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-CD1d (CD1d42, mouse IgG1), anti-CD3 (SK7, mouse IgG1), anti-CD3 (UCHT1, mouse IgG1), anti-CD4 (RPA-T4, mouse IgG1), anti-CD8 (SK1, IgG1), anti-CD14 (M5E2, mouse IgG2a), anti-CD20 (L27, mouse IgG1), anti-CD27 (L128, mouse IgG1), anti-CD161 (BX12, mouse IgG1) (Becton Dickinson).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>d.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Agonistic anti-CD40 (626.1, mouse IgG1, Novartis Vaccine), or agonistic anti-CD40 MAB89 (mouse IgG1, BECKMAN COULTER).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>e.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-human CD19 MicroBeads (Miltenyi Biotec).</Para>
                            </ItemContent>
                          </ListItem>
                        </OrderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Specific monoclonal antibodies used with mouse cells:<OrderedList>
                          <ListItem>
                            <ItemNumber>a.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Non-immune purified rat IgG (Becton Dickinson).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>b.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-mouse CD3 mAb (145.2C11, hamster IgG), anti-mouse NK1.1 (PK135, mouse IgG1) (Becton Dickinson).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>c.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-AsialoGM1 lyophilised antiserum from Cedarline is resuspended in 1 ml of H<Subscript>2</Subscript>0 and it is stable at 4°C for up to 1 year.</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>d.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Mouse CD1d–Ig dimers (Dimerix Technology, Becton Dickinson).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>e.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-mouse CD19 MicroBeads (Miltenyi Biotec).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>f.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Anti-PE MicroBeads (Miltenyi Biotec).</Para>
                            </ItemContent>
                          </ListItem>
                        </OrderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibodies used for human Ig ELISA:<OrderedList>
                          <ListItem>
                            <ItemNumber>a.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Purified anti-human IgM clone JDC-15 (capture) and biotin-conjugated clone G20-127 (detection) (Becton Dickinson).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>b.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Purified polyclonal goat-anti-human IgG (capture) and biotin-conjugated goat anti-human IgG (detection) antisera (Southern Biotechnology).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>c.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Purified anti-human IgG1 clone G18-145 (capture) and biotin-conjugated clone G17-1 (detection).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>d.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Purified anti-human IgE clone G7-18 (capture) and biotin-conjugated clone G7-26 (detection).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>e.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Total human IgM, IgG, IgG<Subscript>1</Subscript>, (from Sigma) and IgE (Calbiochem, Darmstadt, Germany) are used as standards.</Para>
                            </ItemContent>
                          </ListItem>
                        </OrderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibodies used for mouse Ig ELISA:<OrderedList>
                          <ListItem>
                            <ItemNumber>a.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Purified polyclonal goat-anti-mouse IgM, IgG, IgG<Subscript>1</Subscript>, IgG2<Subscript>a/c</Subscript> (capture) and biotin-conjugated goat anti-mouse IgM, IgG, IgG<Subscript>1</Subscript>, IgG2<Subscript>a/c</Subscript> (detection) antisera (Southern Biotechnology).</Para>
                            </ItemContent>
                          </ListItem>
                          <ListItem>
                            <ItemNumber>b.</ItemNumber>
                            <ItemContent>
                              <Para TextBreak="No">Total mouse IgM, IgG, IgG<Subscript>1</Subscript>, IgG2<Subscript>a/c</Subscript> (from Sigma) are used as standards.</Para>
                            </ItemContent>
                          </ListItem>
                        </OrderedList>
                      </Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec5" OutputMedium="Online">
            <Heading>Methods</Heading>
            <Section2 ID="Sec6" OutputMedium="Online">
              <Heading>Purification of PBMCs</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Heparinized peripheral blood from healthy volunteers is diluted 1:3 in RPMI–1% FCS, and layered over 2× volume of Ficoll (Amersham).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The discontinuous gradients are generated by spinning at 400 <Emphasis Type="Italic">g</Emphasis> for 30 min at RT with the brake switched off.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Remove and discard the upper plasma layer without disturbing the ring of mononuclear cells at the plasma–Ficoll interface.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">With a new pipette remove and transfer the PBMCs ring into a new tube.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Dilute the collected PBMCs with 4 volumes of RPMI–1% FCS and centrifuge at 180 <Emphasis Type="Italic">g</Emphasis> for 10 min at +4°C (brake on), to remove residual platelets.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Discard the supernatant, wash PBMCs once again with HBSS, and centrifuge at 200 <Emphasis Type="Italic">g</Emphasis> for 10 min at +4°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Discard the supernatant and resuspend the PBMC pellet in PBS–5% FCS at the appropriate concentration (see below).</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec7" OutputMedium="Online">
              <Heading>Generation of Human iNKT Cell Clones and Lines</Heading>
              <Para TextBreak="No">Human iNKT cells can be obtained by two methods: (i) Cell sorting and cloning ex vivo; (ii) Expansion of iNKT polyclonal cell lines in vitro with the specific antigen αGalCer. iNKT cell clones can be obtained by cloning these cell lines at limiting dilution.</Para>
              <Section3 ID="Sec8" OutputMedium="Online">
                <Heading>Cell Sorting and Cloning of Human iNKT Cells <Emphasis Type="Italic">Ex Vivo</Emphasis>
                </Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Human PBMCs are incubated with PBS+300 ng/ml non-immune mouse IgG for 10 min at RT to block unspecific binding, then with saturating amounts of anti-CD3, anti-Vα24, anti-Vβ11 mAbs on ice. The amount of mAb is determined by titering each of them in separate staining.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">PBMCs are washed three times with FACS-sorting solution and resuspended in PBS–5% FCS at 20–30 × 10<Superscript>6</Superscript> cells/ml. iNKT cells are identified as Vα24 and Vβ11 double positive cells within the CD3<Superscript>+</Superscript> gate. Anti-CD4 mAb can be added to the staining combination to specifically sort CD4<Superscript>+</Superscript> iNKT cells, the subset preferentially endowed with helper function.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">iNKT cells are sorted at 1 cell/well in U-shaped 96-well plates containing 200 μl of RPMI-complete medium, 0,5 μg/ml PHA and 50 U/mL rhIL-2 and 1×10<Superscript>6</Superscript>/ml pooled PBMCs obtained from 2 to 3 different donors and irradiated at 8,000 rad.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">iNKT cell clones are grown at 37°C and 6% CO<Subscript>2</Subscript>. Growing iNKT cell clones are phenotyped for the expression of Vα24, Vβ11 and CD4 coreceptor by flow-cytometry.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec9" OutputMedium="Online">
                <Heading>Expansion of iNKT Cell Polyclonal Cell Lines with the Specific Antigen αGalCer <Emphasis Type="Italic">In Vitro</Emphasis>
                </Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">PBMC are plated at 10<Superscript>6</Superscript> cells/ml at 24-well plates in 2 ml of complete medium containing 10–100 ng/ml of αGalCer. After 48 h, 20 U/ml of rhIL-2 (Novartis, Emeryville, CA, US) are added. IL-2 is then added again at 40 U/ml every 48 h (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 1</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">At day 15–20, αGalCer-induced cell lines are stained with anti-Vβ11, Vα24, and CD4 mAbs as described above (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note</Emphasis>
                          <Emphasis Type="Bold">4</Emphasis>);</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">iNKT cells are sorted by high-speed cell sorting either as bulk cell line or as clones. Vα24<Superscript>+</Superscript>Vβ11<Superscript>+</Superscript>CD4<Superscript>+</Superscript>, Vα24<Superscript>+</Superscript>Vβ11<Superscript>+</Superscript>CD4<Superscript>-</Superscript> T cells are sorted/cloned at 1 cell/well in 96-well plates containing 200 μl of RPMI-complete medium, 0.5 μg/ml PHA and 50 U/ml rhIL-2 and 1×10<Superscript>6</Superscript>/ml pooled PBMCs obtained from 2 to 3 different donors and irradiated at 8,000 rad.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec10" OutputMedium="Online">
                <Heading>Propagation of Human iNKT Cell Clones <Emphasis Type="Italic">In Vitro</Emphasis>
                </Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">iNKT clones or lines are propagated by restimulation every 15–20 days in RPMI-complete medium with a mixture of irradiated allogeneic feeder cells (see above) at 1×10<Superscript>6</Superscript> cells/ml, PHA (0.5 μg/ml) and 50 U/ml rhIL-2.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec11" OutputMedium="Online">
                <Heading>Antigen-Specificity Assays for iNKT Cells</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To verify the antigen-specificity of the iNKT cell clones, 2.5×10<Superscript>4</Superscript> cells are plated in U-bottom 96-well plates with 5×10<Superscript>4</Superscript> of either C1R-CD1d or C1R wt cells in the presence of 50 ng/ml of αGalCer.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">After 48 h, antigen-specific iNKT cell activation is determined by measuring the concentration of IFN-γ and IL-4 in the culture supernatant by ELISA.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec12" OutputMedium="Online">
              <Heading>Human B Lymphocyte Purification</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Human PBMCs are obtained from heparinized peripheral blood of healthy volunteers after density gradient centrifugation on Ficoll–Paque (see above, <Emphasis Type="Italic">see</Emphasis>
                        <Emphasis Type="Bold">Notes 2 and 3</Emphasis>).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">For B cell purification, PBMC are first incubated with PBS+10 μg/ml non-immune mouse IgG for 10 min at RT to block unspecific binding, then anti-CD19 mAb conjugated with magnetic beads are added for further 20 min at 4°C according to manufacture instruction (Miltenyi). Immuno-magnetically labelled B cells are purified on LS+ columns using the MACS® separation system (Miltenyi). All B lymphocyte preparations should be &gt;95% CD20<Superscript>+</Superscript>, the few contaminating cells being CD14<Superscript>+</Superscript>.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec13" OutputMedium="Online">
              <Heading>Human B Cell Helper Assays</Heading>
              <Section3 ID="Sec14" OutputMedium="Online">
                <Heading>B Cell Proliferation Determined by <Superscript>3</Superscript>H-Thymidine Incorporation</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">iNKT cell clones are irradiated at 6,000 rad.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Purified B lymphocytes (0.5–1×10<Superscript>5</Superscript> cells) are plated alone or with irradiated cells of iNKT cell clones at 2:1 ratio in U-bottom 96-well plates containing 0.2 ml of RPMI-complete medium. Duplicate or triplicate wells are stimulated with either 0.2 µg/ml anti-CD3 mAb (UCHT-1) or 50 ng/ml of αGalCer or equal amounts of mouse IgG1 or vehicle.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">After 5 days in culture, 0.5–1 μCi of <Superscript>3</Superscript>H-thymidine is added to each well for 16 h, before cell harvesting and scintillation counting.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec15" OutputMedium="Online">
                <Heading>B Cell Proliferation Determined CFDA-SE Dilution Assay</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Purified B cells are loaded with CFDA-SE to give a final concentration ranging between 0.5 and 5 μM, depending on the duration of the study of cell tracking. Generally, longer duration studies required more intense staining to abrogate the effects of fluorescence decay due to catabolic processes occurring in the absence of cell division <CitationRef CitationID="CR15">(15)</CitationRef>. B cells are incubated for 8 min at room temperature at a cell concentration of 2×10<Superscript>7</Superscript>/ml (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 4</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Labelling is stopped by adding an equal volume of FCS, and washing the cells three times in complete medium.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">CFDA-SE labelled B lymphocytes are seeded at 5×10<Superscript>5</Superscript>/ml in U-bottom wells containing complete medium, with or without 10 μg/ml of agonistic anti-CD40 (626.1, or MAB89) or 50 ng/ml αGalCer, in the presence or in the absence of non-irradiated iNKT cells, at a ratio of 20 B cells to 1 NKT cell.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">After 5 days, CFSE dilution in B cells is determined by four colour-cytofluorimetric analysis using staining for: CFDA-SE, CD27, CD20 and CD3 (to gate out T cells).</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec16" OutputMedium="Online">
                <Heading>Antibody Production <Emphasis Type="Italic">In Vitro</Emphasis>
                </Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Primary autologous or allogeneic B cells and irradiated iNKT cells are cocultured at 2:1 ratio as described above.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">On day 10, culture supernatants are collected and used in ELISA to determine immunoglobulin concentration. IgM, IgG and IgE in the culture supernatants are measured with a sandwich LISA. Briefly, polystyrene microplates are coated with anti-human IgM or IgG or IgE antibodies (10 µg/ml) in coating buffer (Na<Subscript>2</Subscript>CO<Subscript>3</Subscript> 0.18 g/l, NaHCO<Subscript>3</Subscript> 2.1 g/l, NaCl 9 g/l, NaN<Subscript>3</Subscript> 0.2 g/l), pH 8.6 at 4°C overnight. The plates are washed and serial dilutions of the culture supernatants in PBS–FCS are added for 2 h at room temperature. After washing, anti-human IgM or IgG or IgE antibody, coupled to biotin, is added for a further 2 h. After washing, AP-conjugated Strepatividin (Becton Dickinson) is added to wells for 30 min at RT. After final washing, the enzyme bound to the wells is determined using 1 mg/ml <Emphasis Type="Italic">p</Emphasis>-nitrophenyl phosphate (Sigma Chemicals, St. Louis, MO) in 1 M ethanol amine buffer, pH 9.6. The absorbance is read with an automated photometer. The amount of Ig is determined by comparison with a standard curve constructed using known amounts of purified IgM, IgG and IgE.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
            <Section2 ID="Sec17" OutputMedium="Online">
              <Heading>Mouse B Cell Helper Assays with iNKT Cells</Heading>
              <Section3 ID="Sec18" OutputMedium="Online">
                <Heading>Mouse B Cell Purification</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Spleens are obtained from mice under sterile conditions and minced into small fragments by scalpel.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Fragments are gently homogenised on sterile 70 μm cell strainers (Falcon) to obtain a single cell suspension.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Cells are centrifuged 1× at 200 <Emphasis Type="Italic">g</Emphasis> for 5 min at +4°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Resuspend pellet in 10 ml PBS+2% FCS. Add 3 ml ACK solution for 2 min at RT to lyse RBCs.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash 2× and resuspend the pellet at 5×10<Superscript>6</Superscript> cells/ml in PBS–1% FCS and incubated with immunomagnetic anti-CD19 magnetic MicroBeads according to manufacturer’s instructions. Usually, one spleen yields &gt;5×10<Superscript>7</Superscript>purified B cells.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec19" OutputMedium="Online">
                <Heading>Mouse iNKT Cell Purification</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To deplete NK cells from mice, 40 μl of anti-asialoGM1 antiserum is injected i.p. 2 days before iNKT cell purification (<Emphasis Type="Italic">see</Emphasis>
                          <Emphasis Type="Bold">Note 4</Emphasis>).</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Spleen is taken from mice and processed to obtain a single cell suspension as described above.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Spleen cells are deprived of adherent cells by 1 h culture on bacteriological petri dishes in RPMI–1% FCS at 37°C.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
                <Section4 ID="Sec20" OutputMedium="Online">
                  <Heading>Mouse NKT Cell Purification Using Anti-NK1.1 mAb</Heading>
                  <Para TextBreak="No">
                    <OrderedList>
                      <ListItem>
                        <ItemNumber>1.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">To sort total NKT cells, the non-adherent fraction of spleen cells is stained with a saturating dose (pre-determined in pilot experiments) of PE-conjugated anti-NK1.1 mAb for 20 min at 4°C.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>2.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Cells are washed 3× with PBS–1% FCS.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>3.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">NK1.1-PE-labelled total NKT cells incubated with anti-PE magnetic MicroBeads according to manufacturer’s instructions.</Para>
                        </ItemContent>
                      </ListItem>
                    </OrderedList>
                  </Para>
                </Section4>
                <Section4 ID="Sec21" OutputMedium="Online">
                  <Heading>Mouse Primary iNKT Cell Purification Using αGalCer-Loaded CD1d-Dimers</Heading>
                  <Para TextBreak="No">
                    <OrderedList>
                      <ListItem>
                        <ItemNumber>1.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">mCD1d-DimeriX (Becton Dickinson) are loaded with aGalCer o.n. at RT (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note</Emphasis>
                            <Emphasis Type="Bold">5</Emphasis>). Usually, 1 μg dimers/staining is sufficient (<Emphasis Type="Italic">see</Emphasis>
                            <Emphasis Type="Bold">Note 6</Emphasis>).</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>2.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Non-specific binding sites on cells are blocked by incubation with 300 ng of purified non-immune Rat IgG for 20 min at RT.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>3.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">To stain iNKT cells, the non-adherent fraction of spleen cells is stained for 60 min on ice of αGalCer-loaded CD1d-dimers in FACS-sort.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>4.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Wash three times with FACS sort.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>5.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">After washing, αGalCer-loaded CD1d-dimers are revealed by incubations with anti-mouse IgG1-PE mAb (A85-1) for 10 min at +4°C.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>6.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Cells are washed and non-specific antibody binding sites are blocked by incubating 20 min at +4°C with 300 ng each of mouse and rat IgG1 molecules.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>7.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Without washing, cells are incubated with anti-TCR-β-FITC (H57-597) for 10 min at +4°C.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>8.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">iNKT cells are purified using standard fluorescent-based automated cell sorting.</Para>
                        </ItemContent>
                      </ListItem>
                    </OrderedList>
                  </Para>
                </Section4>
                <Section4 ID="Sec22" OutputMedium="Online">
                  <Heading>Mouse iNKT Cell Purification Using αGalCer-Loaded CD1d-Dimers After Expansion <Emphasis Type="Italic">In Vitro</Emphasis>
                  </Heading>
                  <Para TextBreak="No">
                    <OrderedList>
                      <ListItem>
                        <ItemNumber>1.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Total spleen cells are plated in wells of 24 well plates at 10<Superscript>6</Superscript> cell/ml in 2 ml of compete medium containing 50 ng/ml of αGalCer.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>2.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">After 24 h add 50 U/ml of rhIL-2 and 20 ng/ml rmIL-7.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>3.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">Replace fresh cytokines every 48 h.</Para>
                        </ItemContent>
                      </ListItem>
                      <ListItem>
                        <ItemNumber>4.</ItemNumber>
                        <ItemContent>
                          <Para TextBreak="No">At day 12 of culture, stain growing iNKT cells with αGalCer-loaded CD1d-dimers and proceed to purification using standard fluorescent based automated cell sorting as described above.</Para>
                        </ItemContent>
                      </ListItem>
                    </OrderedList>
                  </Para>
                </Section4>
              </Section3>
              <Section3 ID="Sec23" OutputMedium="Online">
                <Heading>Mouse B Cell Helper Assays with Purified Total Splenic NKT Cells (Purified with Anti-NK1.1 Immunomagnetic Sorting)</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">One day before the B cell helper assay, insolubilise the purified anti-CD3 mAb 1452C11 on wells of round-bottom 96-well plates. To each well add 25 μl of a 5 μg/ml solution of the mAb in PBS, and incubate at +4°C. Alternatively, the anti-CD3 mAb can be insolubilised the same day of the B cell helper assay by incubating 2 h at 37°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash wells 4 × times with PBS–5% FCS.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Irradiate the purified NK1.1<Superscript>+</Superscript> T cells at 3,000 rad.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Plate the purified B cells (5×10<Superscript>5</Superscript>) with total irradiated NK1.1<Superscript>+</Superscript> T cells (5×10<Superscript>4</Superscript>) in wells pre-coated with the anti-mouse CD3 mAb in 200 μl of complete medium.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">On day 10, collect culture supernatant and determine the concentration of secreted Igs by ELISA.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec24" OutputMedium="Online">
                <Heading>Mouse B Cell Helper Assays with Purified Splenic iNKT Cells (Purified by Using αGalCer-Loaded CD1d-Dimers and Cell Sorting)</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">One day before the B cell helper assay, insolubilise purified goat anti-rat IgG (mouse and human adsorbed) on wells of round-bottom 96 well plates. This antiserum will cross-link the rat-anti mouse IgG1-Pe mAb utilised to reveal the αGalCer-CD1d-dimers bound to iNKT cells. iNKT cells will be activated upon cross-linking the CD1d-dimers bound to the invariant TCR. To each well add 25 μl of a 10 μg/ml solution of the goat anti-rat IgG Ab in PBS, and incubate at +4°C. Alternatively, the goat anti-rat Ab can be insolubilised the same day of the B cell helper assay by incubating for 2 h at 37°C.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>2.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Wash wells 4 × times with PBS–5% FCS;</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>3.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Irradiate the purified iNKT cells at 3,000 rad;</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>4.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">Plate the purified B cells (5×10<Superscript>5</Superscript>) with irradiated iNKT cells (5×10<Superscript>4</Superscript>) in wells pre-coated with the goat anti-rat Ab in 200 μl of complete medium;</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>5.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">On day 10, collect culture supernatant and determine the concentration of secreted Igs by the ASCs that have differentiated in vitro by ELISA<Emphasis Type="Italic">.</Emphasis>
                        </Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>6.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">As control for the B cell helper assays, purified B cells (5×10<Superscript>5</Superscript>) are in 200 μl of complete medium supplemented with or without +10 μg/ml LPS.</Para>
                      </ItemContent>
                    </ListItem>
                    <ListItem>
                      <ItemNumber>7.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">On day 10, collect supernatant from the culture cultures and determine by ELISA the concentration of secreted.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
              <Section3 ID="Sec25" OutputMedium="Online">
                <Heading>ELISA for Mouse Ig</Heading>
                <Para TextBreak="No">
                  <OrderedList>
                    <ListItem>
                      <ItemNumber>1.</ItemNumber>
                      <ItemContent>
                        <Para TextBreak="No">To determine the amount of IgM and IgG produced by mouse B cells in the helper assays, we follow the ELISA method identical to the one used for human Ig. The following pairs of antibody (Souther Biotechnology) specific for mouse Ig are utilised: purified goat-anti mouse IgM (capture) and biotin-conjugated goat-anti-mouse IgM (detection); purified goat-anti mouse IgG (capture) and biotin-conjugated goat-anti-mouse IgG (detection). The insoluble immune complexes are revealed with AP-conjugated streptavidin as described above for the ELISA detection of human Ig.</Para>
                      </ItemContent>
                    </ListItem>
                  </OrderedList>
                </Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec26" OutputMedium="Online">
            <Heading>Notes</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Human iNKT cell expansion upon αGalCer stimulation in vitro can be variable from donor to donor both in terms of total cell yield and of time required for maximal growth. It is suggested to activate two or three independent PBMCs a time, to select for the best iNKT cells expansion. On average, a time between 15 and 20 days can be considered sufficient to obtain significant iNKT cell expansion in vitro.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Sometimes, B cells obtained from buffy coats are poor responders or are already activated. For this reason, B cells purified from fresh whole blood of healthy donor should be preferred.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">The use of human or mouse sera in helper assays involving human and mouse B cells, respectively, should be avoided as their presence can lead to high background values when culture supernatants are tested in ELISA.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>4.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">CFDA-SE labelling of cells, B cells included, can be quite toxic and reduce the survival of labelled cells in vitro<Emphasis Type="Italic">.</Emphasis> It is therefore critical to titer carefully the minimal concentration of the dye necessary to track the target cells over the desired culturing time vis a vis their maximal survival.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>5.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">40 μl of anti-Asialo GM1 antiserum injected i.p. into mice is usually sufficient to deplete &gt;95% of NK1.1<Superscript>+</Superscript> cells in 24 h. NK cells remain depleted for 3 days.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>6.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">CD1d-DimerX (Becton Dickinson) are loaded with αGalCer on at RT. Efficient Dimer loading requires a 1:9 molar ratio dimers:αGalCer. To determine the amount of αGalCer to use for each loading, apply the following formula:<Equation ID="Equa">
                        <MediaObject>
                          <ImageObject Color="BlackWhite" FileRef="978-1-60327-527-9_2_Chapter_TeX2GIF_Equa.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                        </MediaObject>
                        <EquationSource Format="TEX"><![CDATA[
$${\mu {\rm{g \ di \ }}\alpha {\rm{GalCer}} = \frac{{\mu {\rm{g\  di \ CD1d - Dimer}} \times 9\ {\rm{ (molar \ eccess \ of }}\alpha {\rm{GalCer)}} \times 858\ {\rm{ (MW \ }}\alpha {\rm{GalCer)}}}}{{{\rm{250,000 (MW \ CD1d - Dimer)}}}}}$$
]]></EquationSource>
                      </Equation>
                    </Para>
                    <Para TextBreak="No">The αGalCer-Dimer solution is spun down quickly before using it for staining.</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-527-9_Chapter_2.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Lanzavecchia</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">One out of five peripheral blood B lymphocytes is activated to high-rate Ig production by human alloreactive T cell clones</ArticleTitle>
                <JournalTitle>Eur J Immunol</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>820</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c%2Flsl2ktw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/eji.1830131008</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>6227488</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lanzavecchia A. One out of five peripheral blood B lymphocytes is activated to high-rate Ig production by human alloreactive T cell clones. Eur J Immunol 1983;13:820–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR2">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Lanzavecchia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B.</Initials>
                  <FamilyName>Parodi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F.</Initials>
                  <FamilyName>Celada</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Activation of human B lymphocytes: frequency of antigen-specific B cells triggered by alloreactive or by antigen-specific T cell clones</ArticleTitle>
                <JournalTitle>Eur J Immunol</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>733</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL2c%2FgsVKitg%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/eji.1830130908</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>6604634</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lanzavecchia A, Parodi B, Celada F. Activation of human B lymphocytes: frequency of antigen-specific B cells triggered by alloreactive or by antigen-specific T cell clones. Eur J Immunol 1983;13:733–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR3">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Bendelac</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O.</Initials>
                  <FamilyName>Lantz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME.</Initials>
                  <FamilyName>Quimby</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW.</Initials>
                  <FamilyName>Yewdell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR.</Initials>
                  <FamilyName>Bennink</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RR.</Initials>
                  <FamilyName>Brutkiewicz</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">CD1 recognition by mouse NK1+ T lymphocytes</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>268</VolumeID>
                <FirstPage>863</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXls1Sgs7k%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.7538697</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>7538697</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Bendelac</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PB.</Initials>
                  <FamilyName>Savage</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Teyton</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The Biology of NKT Cells</ArticleTitle>
                <JournalTitle>Annu Rev Immunol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>297</FirstPage>
                <LastPage>336</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltlansr4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.immunol.25.022106.141711</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>17150027</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bendelac A, Savage PB, Teyton L. The Biology of NKT Cells. Annu Rev Immunol 2007;25:297–336.</BibUnstructured>
            </Citation>
            <Citation ID="CR5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P.</Initials>
                  <FamilyName>Dellabona</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E.</Initials>
                  <FamilyName>Padovan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G.</Initials>
                  <FamilyName>Casorati</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Brockhaus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Lanzavecchia</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>180</VolumeID>
                <FirstPage>1171</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXlsFGitL4%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.180.3.1171</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8064234</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med 1994;180:1171–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR6">
              <CitationNumber>6.</CitationNumber>
              <BibUnstructured>Karadimitris A, Gadola S, Altamirano M, et al. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A 2001;98:3294–8. doi: <ExternalRef><RefSource>10.1073/pnas.051604498</RefSource><RefTarget TargetType="DOI" Address="10.1073/pnas.051604498"/></ExternalRef>.</BibUnstructured>
            </Citation>
            <Citation ID="CR7">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL.</Initials>
                  <FamilyName>Matsuda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OV.</Initials>
                  <FamilyName>Naidenko</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Gapin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>192</VolumeID>
                <FirstPage>741</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmtlegtro%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.192.5.741</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10974039</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Matsuda JL, Naidenko OV, Gapin L, et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR8">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Benlagha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Weiss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Beavis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Teyton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Bendelac</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>191</VolumeID>
                <FirstPage>1895</FirstPage>
                <LastPage>903</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXjvFyntLk%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.191.11.1895</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10839805</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J Exp Med 2000;191:1895–903.</BibUnstructured>
            </Citation>
            <Citation ID="CR9">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Kronenberg</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Toward an understanding of NKT cell biology: progress and paradoxes</ArticleTitle>
                <JournalTitle>Annu Rev Immunol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>877</FirstPage>
                <LastPage>900</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktFOju7k%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1146/annurev.immunol.23.021704.115742</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>15771592</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877–900.</BibUnstructured>
            </Citation>
            <Citation ID="CR10">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE.</Initials>
                  <FamilyName>Gumperz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Miyake</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T.</Initials>
                  <FamilyName>Yamamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MB.</Initials>
                  <FamilyName>Brenner</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>195</VolumeID>
                <FirstPage>625</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XitV2nu7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.20011786</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>11877485</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR11">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PT.</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K.</Initials>
                  <FamilyName>Benlagha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Teyton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A.</Initials>
                  <FamilyName>Bendelac</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Distinct functional lineages of human V(alpha)24 natural killer T cells</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>195</VolumeID>
                <FirstPage>637</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XitV2nu7s%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.20011908</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>11877486</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med 2002;195:637–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR12">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G.</Initials>
                  <FamilyName>Galli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Nuti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Tavarini</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">CD1d-restricted help to B cells by human invariant natural killer T lymphocytes</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>197</VolumeID>
                <FirstPage>1051</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXjt1Wls7o%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.20021616</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>12695492</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003;197:1051–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR13">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G.</Initials>
                  <FamilyName>Galli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Nuti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Tavarini</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Innate immune responses support adaptive immunity: NKT cells induce B cell activation</ArticleTitle>
                <JournalTitle>Vaccine</JournalTitle>
                <VolumeID>21</VolumeID>
                <IssueID>Suppl 2</IssueID>
                <FirstPage>S48</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0264-410X(03)00200-7</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>12763683</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Galli G, Nuti S, Tavarini S, et al. Innate immune responses support adaptive immunity: NKT cells induce B cell activation. Vaccine 2003;21 Suppl 2:S48–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR14">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Brossay</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Chioda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N.</Initials>
                  <FamilyName>Burdin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>188</VolumeID>
                <FirstPage>1521</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXmslKlurw%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.188.8.1521</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>9782129</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998;188:1521–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR15">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AB.</Initials>
                  <FamilyName>Lyons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR.</Initials>
                  <FamilyName>Parish</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Determination of lymphocyte division by flow cytometry</ArticleTitle>
                <JournalTitle>J Immunol Methods</JournalTitle>
                <VolumeID>171</VolumeID>
                <FirstPage>131</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c3jtFSjsw%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0022-1759(94)90236-4</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>8176234</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994;171:131–7.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Book>
  </Series>
</Publisher>
